Make us your home page
Instagram

Today’s top headlines delivered to you daily.

(View our Privacy Policy)

Test with live malaria parasites bolsters vaccine hopes

About malaria • Millions in the tropical and subtropical world are infected with malaria each year. • About a million die. • There is no vaccine yet, and preventive drugs are too expensive for most people.

iStockphoto.com

About malaria • Millions in the tropical and subtropical world are infected with malaria each year. • About a million die. • There is no vaccine yet, and preventive drugs are too expensive for most people.

In a daring experiment in Europe, scientists used mosquitoes as flying needles to deliver a "vaccine" of live malaria parasites through their bites.

The results were astounding: Everyone in the vaccine group acquired immunity to malaria; everyone in a nonvaccinated comparison group did not, and developed malaria when exposed to the parasites later.

The study was only a small proof-of-principle test, and its approach is not practical on a large scale. However, it shows that scientists may finally be on the right track to developing an effective vaccine against one of mankind's top killers. A vaccine that uses modified live parasites just entered human testing.

"Malaria vaccines are moving from the laboratory into the real world," Dr. Carlos Campbell wrote in an editorial accompanying the study in today's New England Journal of Medicine. He works for PATH, the Program for Appropriate Technology in Health, a Seattle-based global health foundation.

The new study "reminds us that the whole malaria parasite is the most potent immunizing" agent, even though it is harder to develop a vaccine this way and other leading candidates take a different approach, he wrote.

Malaria kills nearly a million people each year, mostly children under 5 and especially in Africa. Infected mosquitoes inject immature malaria parasites into the skin when they bite; these travel to the liver where they mature and multiply. Then they enter the bloodstream and attack red blood cells — the phase that makes people sick.

People can develop immunity to malaria if exposed to it many times. The drug chloroquine can kill parasites in the final bloodstream phase, when they are most dangerous.

Scientists tried to take advantage of these two factors, by using chloroquine to protect people while gradually exposing them to malaria parasites and letting immunity develop.

They assigned 10 volunteers to a "vaccine" group and five others to a comparison group. All were given chloroquine for three months, and exposed once a month to about a dozen mosquitoes — malaria-infected ones in the vaccine group and non-infected mosquitoes in the comparison group.

That was to allow the "vaccine" effect to develop. Next came a test to see if it was working.

All 15 stopped taking chloroquine. Two months later, all were bitten by malaria-infected mosquitoes. None of the 10 in the vaccine group developed parasites in their bloodstreams; all five in the comparison group did.

The study was done in a lab at Radboud University in Nijmegen, the Netherlands, and was funded by two foundations and a French government grant.

"This is not a vaccine" as in a commercial product, but a way to show how whole parasites can be used like a vaccine to protect against disease, said researcher Dr. Robert Sauerwein.

Two other reports in the New England Journal show that resistance is growing to artemisinin, the main drug used against malaria in the many areas where chloroquine is no longer effective, underscoring the urgent need to develop a vaccine.

Test with live malaria parasites bolsters vaccine hopes 07/29/09 [Last modified: Wednesday, July 29, 2009 5:46pm]
Photo reprints | Article reprints

Copyright: For copyright information, please check with the distributor of this item, Associated Press.
    

Join the discussion: Click to view comments, add yours

Loading...
  1. Senator: American student arrested in China has been freed

    World

    BILLINGS, Mont. — Chinese authorities have dropped charges against an American college student who was arrested and detained in the a week ago after reportedly injuring a taxi driver who was roughing up his mother in a fare dispute, a U.S. lawmaker said Sunday.

    Guthrie McLean was detained for reportedly injuring a taxi driver after the driver physically attacked McLean’s mother.
  2. Tampa-based makeup artist disqualified from contest over pro-Trump post

    News

    WICHITA, Kan. — A makeup artist who splits her time between Tampa and Kansas says she won a national contest sponsored by Kat Von D Beauty but was later disqualified because of an Instagram post supporting Donald Trump's presidential candidacy.

    Gypsy Freeman won the contest with this image posted to Instagram. [@facesofgypsy on Instagram]
  3. Flesh-eating bacteria nearly kills Florida man who thought he just had blisters from a hike

    Health

    Wayne Atkins thought little of the blisters he had gotten while hiking. He was trekking up and down the 4,500-foot-high Mount Garfield in New Hampshire - a 10-mile round trip - and blisters were no surprise.

    Wayne Atkins thought his blisters were from hiking, but the flesh eating bacteria nearly killed him. [YouTube]
  4. Yes, again: Rays blow late two-run lead, get swept by Rangers (w/video)

    The Heater

    ST. PETERSBURG — As weekends go, this was a bad one for the Rays. In a word: brutal.

    Tampa Bay Rays relief pitcher Brad Boxberger, foreground, reacts after giving up a home run to Texas Rangers' Carlos Gomez during the eighth inning of a baseball game Sunday, July 23, 2017, in St. Petersburg, Fla. (AP Photo/Mike Carlson) FLMC116
  5. White House offers muddled message on Russia sanctions legislation

    National

    WASHINGTON - White House press secretary Sarah Huckabee Sanders said Sunday that the Trump administration supports new legislation to punish Russia for its meddling in the 2016 presidential election and its aggression toward Ukraine.

    President Donald Trump at the commissioning ceremony for the USS Gerald R. Ford  at Naval Station Norfolk in Virginia, July 22, 2017. [New York Times]